3.87
-0.26%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rezolute
From its filings with the US Securities and Exchange Commission
Rezolute is based in Redwood City, California and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker RZLT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported a net loss of $77.6m. At that date it held total assets of $112.8m and shareholders' equity of $100.7m.
Rezolute, Inc. (“Rezolute”, the “Company”, “we” or “us”) is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (“HI”).
Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.
Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody down modulates insulin receptor activity, thereby helping to restore glucose to a more normalized range in conditions associated with elevated insulin or insulin-like substances (e.g. IGF-2 variants). Ersodetug shows dose dependent pharmacokinetics with a half-life greater than 2 weeks, which has the potential for monthly dosing. Therefore, we believe that ersodetug is ideally suited as a potential therapy for conditions characterized by HI, and it is being developed to treat any form of HI. As ersodetug acts downstream from the cause of disease and source of HI (insulin or IGF-2 production), it has the potential to be universally effective at treating hypoglycemia related to HI, whether genetic or acquired.
Quoted from its 10-K, filed 24 Sept 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Dec 2011
- Employees
- 71
- Website
- rezolutebio.com ↗
- Head office
- 275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA, 94065
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Nevan ElamActing Chairman of the Board, Chief Executive Officer, since 2013$1.2m
- Mr. Daron EvansChief Financial Officer$384,065
- Dr. Sunil KarnawatChief Commercial Officer
- Dr. Brian RobertsChief Medical Officer$817,959
- Mr. Young-Jin KimDirector, since 2019$45,000
- Mr. Philippe FauchetIndependent Director$90,444
- Mr. Erik HarrisIndependent Director
- Dr. Wladimir HogenhuisIndependent Director$93,444
- Dr. Nerissa KreherIndependent Director$86,444
- Mr. Gilbert LabrucherieIndependent Director$93,444
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rezolute Inc has a strong and experienced management team that brings expertise in the biopharmaceutical industry.
- The company has a diverse product pipeline, with several candidates in different stages of development, which provides potential for future growth.
Weaknesses
- Rezolute Inc operates in a highly competitive industry, facing competition from established players with greater resources.
- The company is relatively smaller in size and has limited financial resources, which may restrict its ability to fully execute on its pipeline.
Opportunities
- The increasing demand for innovative therapeutic solutions presents an opportunity for Rezolute Inc to capture market share with its unique products in development.
- Strategic partnerships and collaborations can provide access to additional resources, expertise, and potentially accelerate development and commercialization.
Threats
- Regulatory challenges and the lengthy approval process pose a threat, potentially delaying market entry and putting pressure on financial resources.
- The uncertainty surrounding healthcare policies and reimbursement systems can impact market access and pricing for Rezolute Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.